Reviewing Lisata Therapeutics (LSTA) and Its Rivals

Lisata Therapeutics (NASDAQ:LSTAGet Rating) is one of 19 public companies in the “Miscellaneous health & allied services, not elsewhere classified” industry, but how does it weigh in compared to its competitors? We will compare Lisata Therapeutics to related businesses based on the strength of its risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Institutional and Insider Ownership

15.6% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by institutional investors. 2.2% of Lisata Therapeutics shares are held by company insiders. Comparatively, 23.9% of shares of all “Miscellaneous health & allied services, not elsewhere classified” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Lisata Therapeutics and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics 0 0 2 0 3.00
Lisata Therapeutics Competitors 32 247 370 30 2.59

Lisata Therapeutics currently has a consensus target price of $15.00, indicating a potential upside of 314.36%. As a group, “Miscellaneous health & allied services, not elsewhere classified” companies have a potential upside of 81.75%. Given Lisata Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Lisata Therapeutics is more favorable than its competitors.

Profitability

This table compares Lisata Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lisata Therapeutics N/A -29.53% -27.96%
Lisata Therapeutics Competitors -2,169.68% -132.55% -27.24%

Volatility & Risk

Lisata Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Lisata Therapeutics’ competitors have a beta of 4.01, indicating that their average stock price is 301% more volatile than the S&P 500.

Valuation & Earnings

This table compares Lisata Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Lisata Therapeutics N/A -$27.47 million -0.30
Lisata Therapeutics Competitors $2.97 billion $132.19 million 10.38

Lisata Therapeutics’ competitors have higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Lisata Therapeutics competitors beat Lisata Therapeutics on 8 of the 13 factors compared.

Lisata Therapeutics Company Profile

(Get Rating)

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.